COMBINATION OF COMPONENTS FOR SUSTENANCE OR IMPROVEMENT OF ELDERLY AND SENIOR AGE PATIENTS’ FUNCTIONAL STATUS (ANTI-AGE MEDICINE)

Cover Page

Cite item

Full Text

Abstract

Aging is a process of changing living systems in time, causing disturbances in their structure and functions, which lead to decrease in the reserve capacity of most systems of the human body and is accompanied by related comorbidities, as well as an increase in mortality. The modern theory of pathogenesis of aging is called inlammaging, originated from the English inflammation - inflammation and aging - aseptic, sterile, mild inflammation that is responsible for processes of aging and age-related comorbidities including osteoarthritis, one of the most common diseases among elderly patients. Drugs, which help to slow down the progression of inflammation and used in combination with non-pharmacological methods of prevention of this condition belong to the group of so-called anti-age medicine, as they reduce the severity of age-related problems and syndromes, as well as contribute to the maintenance/improvement of the functional status of the patient. One of these drugs is Alflutop, which contains a combination of components that have an anti-inflammatory effect on osteoarthritis and inflammaging. This article highlights pathogenetic mechanisms of inflammation caused by aging and osteoarthritis, as well as the points of application of the pharmacological action of the components of the drug Alflutop.

About the authors

Anton P. Pereverzev

Pirogov Russian National Research Medical University

Email: acchirurg@mail.ru
Moscow, Russia

Olga N. Tkacheva

Pirogov Russian National Research Medical University

д-р мед. наук, проф. Moscow, Russia

Darya V. Ermakova

People’s Friendship University of Russia

студентка Moscow, Russia

Yulia V. Kotovskaya

Pirogov Russian National Research Medical University

д-р мед. наук, проф. Moscow, Russia

Olga D. Ostroumova

Pirogov Russian National Research Medical University; Russian Medical Academy of Continuous Professional Education

д-р мед. наук, проф. Moscow, Russia

References

  1. Кишкун А.А. Биологический возраст и старение: возможности определения и пути коррекции. Руководство для врачей. М.: ГЭОТАР-Медиа, 2008. @@Kishkun A.A. Biological age and aging: the possibilities of determining and ways of correction. Ru-kovodstvo dlia vrachei. Moscow: GEOTAR-Media, 2008 (in Russian).
  2. Гериатрия. Национальное руководство. Под ред. О.Н.Ткачевой, Е.В.Фроловой, Н.Н.Яхно. Сер.: Национальные руководства. М.: ГЭОТАР-Медиа, 2018. @@Geriatrics. National leadership. Pod red. O.N.Tkachevoi, E.V.Frolovoi, N.N.Iakhno. Ser.: Natsio-nal'nye rukovodstva. Moscow: GEOTAR-Media, 2018 (in Russian).
  3. Franceschi C, Garagnani P, Parini P et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 2018; 14 (10): 576-90.
  4. Shijin Xia, Xinyan Zhang, Songbai Zheng et al. An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment. J Immunol Res 2016; 2016: 8426874.
  5. Minamino T, Yoshida T, Tatenoetal K. Ras induces vascular smooth muscle cell senescence and in ammation in human atherosclerosis. Circulation 2003; 108 (18): 2264-9.
  6. Quillard T, Charreau B. Impact of Notch signaling on in ammatory responses in cardiovascular disorders. Int J Mol Sci 2013; 14 (4): 6863-88.
  7. Ebersole JL et al. Aging, inflammation, immunity and periodontal disease. Periodontol 2000. 2016; 72: 54-75.
  8. Franceschi C, Garagnani P, Vitale G et al. Inflammaging and "garb-aging". Trends Endocrinol Metab 2017; 28: 199-212.
  9. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med 2014; 69: S4-S9.
  10. Puts MTE, Toubasi S, Andrew MK et al. Interventions to prevent or reduce the level of frailty in community-dwelling older adults: a scoping review of the literature and international policie. Age Ageing 2017; 46: 383-92.
  11. Rydwik E, Frandin K, Akner G. Effects of a physical training and nutritional intervention program in frail elderly people regarding habitual physical activity level and activities of daily living. A randomized controlled pilot study. Arch Gerontol Geriatr 2010; 51: 283-9.
  12. Государственный реестр лекарственных средств. Available at: grls.rosminzdrav.ru @@Gosudarstvennyi reestr lekarstvennykh sredstv. Available at: grls.rosminzdrav.ru (in Russian).
  13. Glyn-Jones S, Palmer AJ, Agricola R et al. Osteoarthritis. Lancet 2015; 386 (9991): 376-87.
  14. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 19902015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388 (10053): 1545-602.1
  15. March L, Smith EU, Hoy DG et al. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol 2014; 28 (3): 353-66.
  16. Jerosch J. E Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. Int J Rheumatol 2011; 2011: 969012.
  17. Yamazaki K, Fukuda K, Matsukawa M et al. Cyclic tensile stretch loaded on bovine chondrocytes causes depolymerization of hyaluronan: involvement of reactive oxygen species. Arthritis Rheum 2003;48:3151-8.
  18. Kurz B, Lemke A, Kehn M et al. Influence of tissue maturation and antioxidants on the apoptotic response of articular cartilage after injurious compression. Arthritis Rheum 2004; 50: 123-30.
  19. Bar-Or D, Rael LT, Thomas GW, Brody EN. Inflammatory Pathways in Knee Osteoarthritis: Potential Targets for Treatment. Curr Rheumatol Rev 2015; 11 (1): 50-8.
  20. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5 (2): 77-94.
  21. Панасюк А.Ф., Ларионов Е.В. Хондроитинсульфаты и их роль в обмене хондроцитов и межклеточного матрикса хрящевой ткани. Научно-практическая ревматология. 2000; 2: 46-55. @@Panasiuk A.F., Larionov E.V. Khondroitinsul'faty i ikh rol' v obmene khondrotsitov i mezhkletoch-nogo matriksa khriashchevoi tkani. Nauchno-prakticheskaia revmatologiia. 2000; 2: 46-55 (in Russian).
  22. Stabler TV, Huang Z, Montell E et al. Chondroitin sulphate inhibits NF-kB activity induced by interaction of pathogenic and damage associated molecules. Osteoarthritis Cartilage 2017; 25: 166-74.
  23. Бадокин В.В. Клиническая оценка фармакологической активности препарата хондроитина сульфат. Лечащий врач. 2012; 10: 92. @@Badokin V.V. Klinicheskaia otsenka farmakologicheskoi aktivnosti preparata khondroitina sul'fat. Lechashchii vrach. 2012; 10: 92 (in Russian).
  24. Mocchegiani E, Costarelli L, Giacconi R et al. Nutrient-gene interaction in ageing and successful ageing. A single nutrient (zinc) and some target genes related to inflammatory/immune response. Mechanisms Ageing Development 2006; 127 (6): 517-25.
  25. Claxon A, Morris C, Blake D et al. The anti-inflammatorv efectsof D-myo-inositol-1.2.6-trisphospha-te (PP56) on animal models of inflammation. Agents Actions 1990; 29: 68-70.
  26. Kidd BL, Cruwys S, Mapp PI, Blake DR. Role of thesympathetic nervous system in chronic joint pain and inflammation. Ann RheumaticDis 1992; 51: 1188-91.
  27. Ostrin EJ et al. Myo-Inositol Reduces Pro-Tumoral IL6 Inflammation in a Mouse Model of Lung Cancer Chemoprevention. Am J Respir Crit Care Med 2017; 195: A4955.
  28. Saxena RN, Pendse VK, Khanna NK. Anti-inflammatory and analgesic properties of four aminoacids. Ind J Physiol Pharmacol 1984; 28 (4): 299-305.
  29. Олариу Л., Димитриу Б., Бусэ Э., Росоиу Н. In vitro эффект препарата алфлутоп на некоторые внеклеточные сигнальные факторы, участвующие в воспалении при остеоартрите. Вестн. Академии румынских ученых. Статьи по биологическим наукам. 2015; 4 (2).
  30. Олариу Л., Пятигорская Н., Димитриу Б. и др. In vitro хондровосстановительная способность препарата алфлутоп, доказанная на культурах хондроцитов. Roman Biotech Letters 2016; 22 (6).
  31. Ndeh D, Munoz Munoz J, Cartmell A et al. The human gut microbe Bacteroides thetaiotaomicron encodes the founding member of a novel glycosaminoglycan-degrading polysaccharide lyase family PL29. JBC 2018; 293 (46): 17906-16. [Olariu L., Piatigorskaia N., Dimitriu B. et al. In vitro khondrovosstanovitel'naia sposobnost' preparata alflutop, dokazannaia na kul'turakh khondrotsitov Roman Biotech Letters 2016; 22 (6) (in Russian).]
  32. Алексеева Л.И., Таскина Е.А., Лила А.М. и др. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп® в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. Современная ревматология. 2019. 13 (3): 51-9.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies